255 General Discussion 16. Wemelsfelder, M. L. et al. Extensive red blood cell matching considering patient alloimmunization risk. Vox Sang. 119, 368–376 (2024). 17. Vyas, R. et al. Unlocking the potential: ChatGPT and the quest for reliable blood transfusion information. J. Med. Artif. Intell. 7, 17–17 (2024). 18. Fariman, S. K. et al. A robust optimization model for multi-objective blood supply chain network considering scenario analysis under uncertainty: a multi-objective approach. Sci. Rep. 14, 9452 (2024). 19. Pérez-Aliaga, A. I. et al. Routine results of an algorithm for managing the production of blood components. Vox Sang. 119, 541–547 (2024). 20. Schönborn, L. et al. Longitudinal Changes in the Blood Supply and Demand in North- East-Germany 2005-2015. Transfus. Med. Hemotherapy 44, 224–231 (2017). 21. Greinacher, A. et al. A population-based longitudinal study on the implications of demographics on future blood supply. Transfusion (Paris) 56, 2986–2994 (2016). 22. Van Hoeven, L., Koopman, R., Koffijberg, H., Roes, K. & Janssen, M. Historical time trends in red blood cell usage in the Netherlands. Int. J. Clin. Transfus. Med. Volume 4, 67–77 (2016). 23. Tinegate, H. et al. Ten-year pattern of red blood cell use in the North of England. Transfusion (Paris) 53, 483–489 (2013). 24. Jones, J. M. et al. Slowing decline in blood collection and transfusion in the United States – 2017. Transfusion (Paris) 60, (2020). 25. Borkent-Raven, B. A., Janssen, M. P. & Van Der Poel, C. L. Demographic changes and predicting blood supply and demand in the Netherlands. Transfusion (Paris) 50, 2455– 2460 (2010). 26. Decision Making under Deep Uncertainty: From Theory to Practice. (Springer International Publishing, Cham, 2019). doi:10.1007/978-3-030-05252-2. 27. Prevot, J. & Jolles, S. Global immunoglobulin supply: steaming towards the iceberg? Curr. Opin. Allergy Clin. Immunol. 20, 557–564 (2020). 28. SUPPLY. SUPPLY Project. SUPPLY Project https://supply-project.eu/. 29. Mielke, O. et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. J. Peripher. Nerv. Syst. 24, 72–79 (2019). 30. on behalf of the OPTIC study group et al. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC). Trials 22, 155 (2021). 31. Adrichem, M. E. et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 145, 1641–1652 (2022).
RkJQdWJsaXNoZXIy MTk4NDMw